News

stern and unapologetic

How politically heated is the present moment? Enough to elicit verbal violence from trusted nurses. 

AISAP, an Israeli healthcare technology company focused on using artificial intelligence (AI) to enhance medical imaging results, has gained U.S. Food and Drug Administration (FDA) clearance for its new point-of-care ultrasound (POCUS) software platform, AISAP Cardio.

Researchers see potential for this technology to make cardiac screening much easier for physicians who are not trained cardiologists.

The American Board of Cardiovascular Medicine is still pushing forward with its efforts to change how cardiologists are certified in the United States. While the group can reapply in the future for a standalone cardiology board, it is also looking at possible partnerships with other organizations.

Thumbnail

The American Stroke Association's first major update in 7 years highlights the importance of coordinated care and expands patient access to critical treatments. It also includes the first detailed recommendations for treating stroke in pediatric patients.

SNMMI Image of the Year 68Ga-FAPI-46 PET/CT heart attack acute myocardial infarction

More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.

Chris Waddell Abbott

Chris Waddell, a medtech executive focused on various structural heart technologies, is leaving Abbott after several years to "recharge" and pursue a new opportunity.

Trinity Health

Danbury, Connecticut-based Advanced Imaging Specialists previously sued Trinity Health in November and is now prepared to vacate their contract amid ongoing challenges. 

hologic

The Marlborough, Massachusetts-based mammography systems manufacturer revealed details about the litigation in a Jan. 26 filing with the U.S. Securities and Exchange Commission.

The 39-year-old vascular surgeon allegedly killed his ex-wife and her husband on Dec. 30. If convicted, he faces the possibility of life in prison without parole.

The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.

The Boston Scientific Seismiq intravascular lithotripsy (IVL) system entered commercial use in the U.S. in January 2026.

Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.

Gene editing software image from Scribe Therapeutics for its STX-1150 drug to treat LDL-C.

Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.

Around the web

How politically heated is the present moment? Enough to elicit verbal violence from trusted nurses.